nervine-sedative

Skullcap

Scutellaria lateriflora L.

The Nerve Unclencher

Crystalis is a reference resource for herbal, crystal, and somatic practice.

This library is designed to help readers orient, compare, and research. It is not a substitute for medical care or practitioner judgment.

Botanical / editorial

Family
Lamiaceae
Plant type
Aerial parts (leaves and flowering tops)
Route
Mixed route
Evidence tier
Mixed evidence
North America and parts of Europe1000+Lamiaceae

Botanical / meta

Botanical identity

Pharmacognosy intro

Scutellaria lateriflora L. (Lamiaceae), commonly known as American skullcap, mad-dog skullcap, or blue skullcap, is a perennial herbaceous plant native to North America and parts of Europe. The species holds a distinguished position in the pharmacopoeia of Eclectic medicine and Native American healing traditions, where it was employed as a nervine, antispasmodic, and treatment for rabies (hence "mad-dog"). The aerial parts constitute the primary medicinal material, harvested during the flowering period to maximize phytochemical yield. The chief bioactive constituents of S. lateriflora are flavonoids, which include baicalin (approximately 40 mg/g in 50% ethanol extract), baicalein (approximately 33 mg/g in 95% ethanol extract), scutellarein A, apigenin, oroxylin A, wogonin, chrysin, and daidzein. The plant also contains endogenous GABA (1.6 mg/g in ethanol and aqueous extracts) and glutamine (31 mg/g in aqueous extract). Additional flavonoids identified include genkwanin, hesperetin, quercetin, rutin, and naringenin. The phenylethanoid glycoside verbascoside has also been isolated from this species. The primary mechanism of anxiolytic action involves positive allosteric modulation at the benzodiazepine (BDZ) binding site of the GABA-A receptor. Baicalin, baicalein, wogonin, and apigenin each demonstrate GABAergic properties through this receptor interaction, enhancing chloride ion conductance and producing downstream inhibitory neurotransmission. Additionally, certain S. lateriflora flavonoids demonstrate binding affinity at the serotonin 5-HT7 receptor, suggesting a dual mechanism of action involving both GABAergic and serotonergic pathways. This polypharmacological profile distinguishes skullcap from single-target anxiolytics and may account for its broad-spectrum calming effects without significant cognitive impairment. In a randomized, double-blind, placebo-controlled crossover study (n=43), 350 mg of S. lateriflora extract administered three times daily for two weeks significantly enhanced global mood as measured by the Profile of Mood States (p < 0.001), without reduction in energy or cognition. The Beck Anxiety Inventory did not reach significance (p = 0.191), which was attributed to a floor effect in the largely non-anxious healthy volunteer population. Preclinical animal models in Sprague-Dawley rats demonstrated that S. lateriflora extract significantly increased open field entries, head dips, and time spent in open arms in the elevated plus-maze paradigm, consistent with GABA-mediated anxiolysis.

Editorial orientation

The Nerve Unclencher

Skullcap is usually reached for when the body is tired but still electrically busy. It belongs first to the frayed-nervine lane, not to heavy sedation.

Door 1

Body-first read

Hook

Skullcap makes the most sense when the page stays close to overstimulation. The aerial parts are light, green, and more exact than they look. This is a herb for jangly exhaustion, twitchy reactivity, and the state where mental overrun has started living in the muscles. Public authority is strongest when skullcap is kept in nervine language and not inflated into a universal sleep herb. It helps because it loosens the over-signaling rather than knocking the person flat.

What it is for

Scutellaria lateriflora L. (Lamiaceae), commonly known as American skullcap, mad-dog skullcap, or blue skullcap, is a perennial herbaceous plant native to North America and parts of Europe. The species holds a distinguished position in the pharmacopoeia of Eclectic medicine and Native American healing traditions, where it was employed as a nervine, antispasmodic, and treatment for rabies (hence "mad-dog"). The aerial parts constitute the primary medicinal material, harvested during the flowering period to maximize phytochemical yield. The chief bioactive constituents of S. lateriflora are flavonoids, which include baicalin (approximately 40 mg/g in 50% ethanol extract), baicalein (approximately 33 mg/g in 95% ethanol extract), scutellarein A, apigenin, oroxylin A, wogonin, chrysin, and daidzein. The plant also contains endogenous GABA (1.6 mg/g in ethanol and aqueous extracts) and glutamine (31 mg/g in aqueous extract). Additional flavonoids identified include genkwanin, hesperetin, quercetin, rutin, and naringenin. The phenylethanoid glycoside verbascoside has also been isolated from this species. The primary mechanism of anxiolytic action involves positive allosteric modulation at the benzodiazepine (BDZ) binding site of the GABA-A receptor. Baicalin, baicalein, wogonin, and apigenin each demonstrate GABAergic properties through this receptor interaction, enhancing chloride ion conductance and producing downstream inhibitory neurotransmission. Additionally, certain S. lateriflora flavonoids demonstrate binding affinity at the serotonin 5-HT7 receptor, suggesting a dual mechanism of action involving both GABAergic and serotonergic pathways. This polypharmacological profile distinguishes skullcap from single-target anxiolytics and may account for its broad-spectrum calming effects without significant cognitive impairment. In a randomized, double-blind, placebo-controlled crossover study (n=43), 350 mg of S. lateriflora extract administered three times daily for two weeks significantly enhanced global mood as measured by the Profile of Mood States (p < 0.001), without reduction in energy or cognition. The Beck Anxiety Inventory did not reach significance (p = 0.191), which was attributed to a floor effect in the largely non-anxious healthy volunteer population. Preclinical animal models in Sprague-Dawley rats demonstrated that S. lateriflora extract significantly increased open field entries, head dips, and time spent in open arms in the elevated plus-maze paradigm, consistent with GABA-mediated anxiolysis.

Skullcap is usually reached for when the body is tired but still electrically busy. It belongs first to the frayed-nervine lane, not to heavy sedation.

Route panel

Preparation shapes the claim

Evidence and safety may differ by preparation. Essential oil, tea, tincture, extract, infused oil, and topical use are not interchangeable.

Mixed route

Comparison

What makes this herb distinct

Comparison intro

Skullcap often sits beside passionflower and blue vervain because all three meet nervous overrun, but skullcap is usually the cleanest fit for frazzled depletion.

Comparison rule

Choose skullcap when the system looks spent, overstimulated, and unable to release. Keep passionflower for looping thought and blue vervain for held jaw-and-neck tension.

Quality

Fresh, dried, oil, and garden read

Fresh

Fresh skullcap should smell green and bitter-clean, not sour or limp.

Dried

Dried skullcap should still show color and structure. Brown dust is a weak nervine.

Oil lane

Skullcap is not an oil herb. The strongest lane is tea, tincture, and extract.

Growing tips

Skullcap likes moisture, light, and regular cutting before it goes coarse.

Companion

Crystal pairing reference

Why this pairing exists

With fluorite, skullcap reads as cleaner signal and less internal static.

Skullcap and lepidolite share a nervous system state best described as ventral vagal with gentle downregulation of sympathetic overdrive. Where skullcap's baicalin and wogonin modulate GABA-A receptor activity to reduce neuronal excitability, lepidolite's lithium-rich composition has been traditionally associated with emotional stabilization and the easing of cyclical anxious thought patterns. Neither agent produces the heavy sedation of dorsal vagal collapse; instead, both facilitate the transition from fight-or-flight hyperarousal into a state of calm engagement. The pairing is particularly effective during evening wind-down rituals. A cup of skullcap infusion held alongside a piece of lepidolite during a seated breathing practice creates a multi-sensory environment that reinforces parasympathetic activation. The warmth of the tea activates thermoreceptors that promote vagal tone, while the physical weight of the stone in the non-dominant hand provides proprioceptive grounding. This combination addresses the common pattern of "wired but tired", the sympathetic nervous system running on residual cortisol while the body craves rest. For practitioners working with clients who experience racing thoughts at bedtime, the skullcap-lepidolite pairing offers a non-pharmaceutical protocol. The herb addresses the neurochemical component (GABAergic modulation) while the crystal provides a tactile anchor for mindfulness practice, interrupting the rumination loop that feeds insomnia.

Crystal side

Companion crystal

Door 2

Compound and clinical layer

Clinical and compound notes are included as a research layer, not as treatment instructions.

Safety intro

Contraindications: No absolute contraindications are well-established in the clinical literature. However, due to its GABAergic mechanism, concurrent use with benzodiazepines (diazepam, lorazepam, alprazolam), barbiturates, and other CNS depressants may produce additive sedation. Caution is warranted with alcohol co-administration. Pregnancy/Lactation: Insufficient safety data. Classified as "avoid" during pregnancy and lactation by most pharmacognosy authorities due to lack of teratogenicity and reproductive toxicity studies. Hepatotoxicity: Historically, cases of liver injury attributed to skullcap were later determined to result from adulteration with germander (Teucrium chamaedrys), which contains hepatotoxic neo-clerodane diterpenes. Authenticated S. lateriflora does not appear to carry intrinsic hepatotoxic risk at recommended doses. Dosage Ranges: Dried herb: 1-2 g three times daily as infusion. Tincture (1:5, 45% ethanol): 2-4 mL three times daily. Standardized extract: 350 mg three times daily (clinical trial dosing). No standardized extract concentration has been officially established. Adverse Reactions: In clinical trials, no significant adverse events were reported at 1,050 mg/day over two weeks. Historical reports of hepatotoxicity at an estimated incidence of < 0.01% were linked to adulterated products rather than authentic material. Mild drowsiness is the most commonly reported effect.

Resource framing

Crystalis is a reference resource for herbal, crystal, and somatic practice.

This library is designed to help readers orient, compare, and research. It is not a substitute for medical care or practitioner judgment.

Clinical and compound notes are included as a research layer, not as treatment instructions.

Evidence and safety may differ by preparation. Essential oil, tea, tincture, extract, infused oil, and topical use are not interchangeable.